Next Article in Journal
Are Two-Centimeter Breast Cancers Large or Small?
Previous Article in Journal
hpv is Here to Stay
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 4
10.3747/co.20.1231
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis

by
T. Qin
1,
Z.Y. Yuan
1,
R.J. Peng
1,
Y.D. Zeng
2,
Y.X. Shi
1,
X.Y. Teng
1,
D.G. Liu
1,
B. Bai
1 and
S.S. Wang
1,*
1
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510275, China
2
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510275, China
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(4), 196-204; https://doi.org/10.3747/co.20.1231
Submission received: 2 May 2013 / Revised: 6 June 2013 / Accepted: 9 July 2013 / Published: 1 August 2013

Abstract

Background: Given the use of tamoxifen as standard treatment for hormone receptor–positive breast cancer, the use of toremifene as an adjuvant endocrine therapy has not been widely examined. The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor–positive breast cancer in premenopausal women. Methods: Premenopausal patients with hormone receptor–positive operable breast cancer were eligible. Enrolled patients (n = 1847) received either 60 mg toremifene (n = 396) or 20 mg tamoxifen (n = 1451) daily for a minimum of 5 years after surgery. Disease-free survival (DFS) was the primary endpoint. Overall survival (OS) and time to distant recurrence were secondary endpoints. Results: Treatment with toremifene and tamoxifen resulted in no between-group differences in DFS (p = 0.659) or OS (p = 0.364). Mean DFS was 10.3 years for both groups. Mean OS was 11.2 years for the toremifene group and 11.1 years for tamoxifen group. The 5-year DFS rate was 87.0% in the toremifene group and 85.0% in the tamoxifen group. The 5-year survival rate was 94.3% in the toremifene group and 93.5% in the tamoxifen group. Adverse events rates were similar in the two groups, with the exception of irregular menses, which occurred at a higher rate in the tamoxifen group than in the toremifene group (10.0% vs. 6.3%, p = 0.025). Conclusions: In this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor–positive breast cancer in premenopausal women were similar.
Keywords: tamoxifen; toremifene; breast cancer; adjuvant endocrine therapy; premenopausal tamoxifen; toremifene; breast cancer; adjuvant endocrine therapy; premenopausal

Share and Cite

MDPI and ACS Style

Qin, T.; Yuan, Z.Y.; Peng, R.J.; Zeng, Y.D.; Shi, Y.X.; Teng, X.Y.; Liu, D.G.; Bai, B.; Wang, S.S. Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis. Curr. Oncol. 2013, 20, 196-204. https://doi.org/10.3747/co.20.1231

AMA Style

Qin T, Yuan ZY, Peng RJ, Zeng YD, Shi YX, Teng XY, Liu DG, Bai B, Wang SS. Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis. Current Oncology. 2013; 20(4):196-204. https://doi.org/10.3747/co.20.1231

Chicago/Turabian Style

Qin, T., Z.Y. Yuan, R.J. Peng, Y.D. Zeng, Y.X. Shi, X.Y. Teng, D.G. Liu, B. Bai, and S.S. Wang. 2013. "Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis" Current Oncology 20, no. 4: 196-204. https://doi.org/10.3747/co.20.1231

APA Style

Qin, T., Yuan, Z. Y., Peng, R. J., Zeng, Y. D., Shi, Y. X., Teng, X. Y., Liu, D. G., Bai, B., & Wang, S. S. (2013). Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis. Current Oncology, 20(4), 196-204. https://doi.org/10.3747/co.20.1231

Article Metrics

Back to TopTop